Savara Inc. announced that Dave Lowrance, its Chief Financial and Administrative Officer, will step down on July 15, 2026, due to health reasons. The company will separate financial and administrative duties, with COO Robert Lutz assuming the CFO role. This leadership change aims to ensure smooth financial management as Savara advances its clinical-stage biopharmaceutical programs, including MOLBREEVI for rare respiratory diseases. The transition reflects the company's focus on strong governance and operational continuity.
Ripple's XRP experienced a surge in aggressive buying from derivatives traders, pushing its price up by 5.35% in 24 hours and lifting the taker buy-sell ratio above 1. However, a spike in Coin Days Destroyed indicates significant profit-taking as dor...
MSC Industrial Direct Co., Inc. reported strong fiscal Q3 earnings driven by temporary industry tailwinds. However, the company's long-term outlook is modest due to slow overall market growth and stronger competitors like GWW and FAST. An analyst est...
Binance recorded a net inflow of $213 million in USDT stablecoins over 24 hours, indicating increased capital moving onto the exchange. This inflow suggests traders may be preparing to buy cryptocurrencies or use the funds for trading activities, but...
Revolut sold $1.2 million worth of AVAX, sparking questions about corporate crypto strategies, but this sale appears isolated without signaling a broad trend. Exchange data shows net outflows of AVAX, indicating buyers are absorbing supply rather tha...
Over 665 billion Shiba Inu (SHIB) tokens became active in the last 24 hours, driven by increased activity from large holders or whales. Despite this large injection, SHIB's price remains weak around $0.0000043, trading below key moving averages and f...
